Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
CAMBRIDGE, Mass. and EXTON, Pa., April 11, 2016 -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that Idera’s Chief Executive Officer, Vincent Milano will present at the 15th Annual Needham Healthcare Conference on Tuesday, April 12, 2016 at 3:40 p.m. Eastern Time at the Westin Grand Central Hotel in New York City.
Live audio webcast of Idera’s presentations will be accessible in the Investors and Media section of Idera’s website at http://www.iderapharma.com. Archived versions will also be available on the Company’s website after the event for 90 days.
About Idera Pharmaceuticals
Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment of certain cancers and rare diseases. Idera’s proprietary technology involves using a TLR-targeting technology, to design synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. In addition to its TLR programs, Idera has created a third generation antisense technology platform using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA. To learn more about Idera, visit www.iderapharma.com.
Investor and Media Contact Robert Doody VP, IR & Corporate Communications 617-679-5515 (office) 484‐639‐7235 (mobile) [email protected]
